ReviewGland surgery2026
Optimization of fat grafting to attenuate radiation damage: a narrative review.
Review in Gland surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Radiation-induced fibrosis (RIF) remains a progressive complication of cancer therapy that compromises tissue quality and reconstructive outcomes. Autologous fat grafting (AFG) has emerged as a regenerative strategy to mitigate radiation damage. However, clinical outcomes remain variable, and efforts to enhance outcomes have largely focused on improving graft survival, angiogenesis, and reduction of fibrotic remodeling. This review aims to highlight recent advances in fat grafting to resolve fibrosis and new evidence for closely related adverse conditions. Methods: In this narrative review, an overview of existing knowledge and recent research in the use of fat grafting to attenuate RIF is presented. The article is based on a literature search in PubMed with the keywords "fat graft" and "adipose" in addition to the senior authors' clinical experience in breast reconstruction. Key Content and Findings: Research continues to evaluate specific adipose-derived stem cell (ADSC) populations to improve graft survival with limited progress towards clinical application. In addition, several pharmacological strategies combined with AFG have been evaluated in murine models to mitigate RIF and improve fat graft outcomes. Emerging data on decellularized adipose matrix (DAM) shows promise and may be ideal for patients with insufficient adipose tissue. Given the ADSC population variability between donors, research studies could benefit from analyzing the adipose tissue as this remains poorly characterized. Most strategies involved in AFG enrichment involve procedures that would require Good Manufacturing Practice (GMP) handling or use of medicines outside of their indications, which would be considered burdensome in a clinical setting. Conclusions: This review examines current cellular therapy, pharmacologic treatments, and prophylactic strategies aimed at enhancing fat graft survival and discusses applications beyond attenuating fibrosis with specific indications focused on resolving secondary lymphedema, neuropathic pain, and wound healing with promising though limited clinical evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.